Compare iShares Global Clean Energy ETF (ICLN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Novo Nordisk A/S — how do they compare? iShares Global Clean Energy ETF trades at $18.38, while Novo Nordisk A/S trades at $46.22 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals.
| ICLN | NVO | |
|---|---|---|
52-Week High | $23.75 | $63.98 |
52-Week Low | $13.66 | $35.29 |
Market Cap | — | $207.85B |
Sector | — | Health |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN is trading at $18.395, up 1.74% today, with a bearish technical signal from moving averages. The ETF provides exposure to 105 global renewable energy companies but faces competition from traditional energy ETFs offering lower fees and higher yields. Recent news highlights clean energy's 25% gains in 2026, though policy uncertainties and geopolitical tensions pose risks.
The outlook remains mixed with structural growth in clean energy demand balanced against regulatory headwinds and expense ratio disadvantages. Key opportunities include global energy transition trends, while risks involve U.S. permit delays and Chinese supply chain tensions affecting solar development.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
